K. Mathurin

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada

BackgroundBipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated with a favourable metabolic profile and minimal weight gain potential. This study aimed to assess the economic impact of asenapine compared to olanzapine in the treatment of BPD in Canada.MethodsA decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine compared with olanzapine. The decision tree takes into account the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases (CHDs), and stroke. Analyses were conducted from both a Canadian Ministry of Health (MoH) and a societal perspective over a five-year time horizon with yearly cycles.ResultsIn the treatment of BPD, asenapine is a dominant strategy over olanzapine from both a MoH and a societal perspective. In fact, asenapine is associated with lower costs and more quality-adjusted life years (QALYs). Results of the probabilistic sensitivity analysis indicated that asenapine remains a dominant strategy in 99.2% of the simulations, in both a MoH and a societal perspective, and this result is robust to the many deterministic sensitivity analyses performed.ConclusionsThis economic evaluation demonstrates that asenapine is a cost-effective strategy compared to olanzapine in the treatment of BPD in Canada.

Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada.

To assess, from a Canadian perspective, the economic impact of arsenic trioxide (ATO) + all‐trans retinoic acid (ATRA) for treating newly diagnosed acute promyelocytic leukaemia (APL), the cost‐effectiveness of ATO + ATRA compared to ATRA + idarubicin (IDA) was assessed over a lifetime horizon using a time‐dependent Markov model. The model considers four health states: complete remission, treatment failure or relapse, post‐failure, and death. Markov cycle length was 1 month for the first 48 months and 1 year thereafter. Efficacy outcomes in terms of event‐free survival and overall survival were taken from a head‐to‐head clinical trial. Costs were associated with drug and administration, adverse events (AEs), treatment of relapses, follow‐up visits, and productivity losses. Utilities and disutilities associated with health states and AEs were derived from the literature. Compared to ATRA + IDA, ATRA + ATO is associated with incremental cost‐effectiveness ratios (ICERs) of

Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada

CAD50,193/quality‐adjusted life years (QALY) and

PMH38 Cost-Effectiveness of Asenapine in the Treatment of Schizophrenia in Canada

CAD50,338/QALY from a Canadian Ministry of Health (MoH) and societal perspectives, respectively. Results of the one‐way sensitivity analysis show that ICER varied from

A Global Economic Model to Assess the Cost Effectiveness of New Treatments for Advanced Breast Cancer in Canada

CAD23,045 to

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD

CAD60,759/QALY (MoH perspective) and from

Cost-Effectiveness Of Bendamustine+Rituximab Versus Fludarabine+Rituximab In The Treatment Of Relapsed Indolent Non-Hodgkin's And Mantle Cell Lymphomas In Canada

CAD23,120 to

PSU14 Economic Impact of Scoliosis in Canada: A RAMQ Database Analysis

CAD60,905/QALY (societal perspective). ATO in the first‐line therapy for patients with APL can be considered a more cost‐effective strategy than standard treatment from a Canadian perspective. Copyright

PMH37 Cost-Effectiveness of Asenapine in the Treatment of Bipolar I Disorder in Canada

Acute promyelocytic leukemia (APL) is an uncommon type of acute leukemia characterized by high early mortality. Current first‐line treatments include all‐trans retinoic acid (ATRA), anthracyclines, and other conventional chemotherapies (CTs). Although APL is generally associated with a good prognosis, about 20% of patients who achieve remission subsequently relapse and are resistant to the previously administrated treatment. The objective of this study was to assess, from a Canadian perspective, the economic impact of arsenic trioxide (ATO) compared to ATRA+CT for treatment of patients with relapsed/refractory APL.

Development of a Global Model for the Economic Evaluation of Personalized Medicine for the Treatment of Prostate Cancer

Objective: Asenapine is the first tetracyclic antipsychotic approved in Canada for the treatment of schizophrenia (SCZ). Asenapine has shown a comparable efficacy profile to other atypical antipsychotics and it is associated with a favourable metabolic profile and less weight gain. This study aimed to assess the economic impact of asenapine compared to other atypical antipsychotics in the treatment of SCZ in Canada. Methods: A decision tree combined with a Markov model was constructed to assess the cost-utility of asenapine compared with other atypical antipsychotics. The decision tree takes into account the occurrence of extrapyramidal symptoms, the probability of switching to a different antipsychotic, and the probability of gaining weight. The Markov model takes into account long-term metabolic complications including diabetes, hypertension, coronary heart diseases, and stroke. In the base-case analysis, asenapine was compared to olanzapine. Asenapine was also compared with other atypical antipsychotics commonly used in Canada in alternative scenarios. Analyses were conducted from both Canadian Ministry of Health (MoH) and societal perspectives over a 5-year time horizon.